United States Patent 6,706,276: scope, claim coverage, and US patent landscape for vaginal antimicrobial-contraceptive matrix formulations
Executive summary. US Patent 6,706,276 claims vaginal compositions and related use methods that are simultaneously (i) antimicrobial and contraceptive, (ii) matrix-forming and bio-adhesive, (iii) buffered to maintain acidic vaginal pH (<5, and in dependent claims about pH 3.5-4.5 in semen presence), and (iv) hypertonic, with semen contact producing semisolid matrix formation and cervical mucus hardening. The independent claim set is composition-centric and method-centric, plus a separate “solid composition” dispersible form. Claim scope is broad in polymer, buffering, humectant, preservative, and optional antimicrobial/contraceptive agent selection via Markush groups, while tightening via numeric ranges (typically 1-10% each key polymer/buffer component; narrower preferred ranges in dependents) and functional limitations (matrix/adhesion, pH maintenance against semen, mucus hardening, microbiological balance preservation). The optional-agent dependent claims expand coverage to specific known actives (notably nonoxynol-9 and multiple antifungals/antiprotozoals), creating compound-and-combination overlay risk for later formulators and generic/line-extension entrants.
How broad are the claims in US Patent 6,706,276, and what exactly do they cover?
Short answer (scope map). The patent claims a vaginal drug-delivery concept: a hypertonic, buffered, bio-adhesive matrix that (a) forms a semisolid matrix on semen contact, (b) hardens cervical mucus, (c) maintains acidic vaginal pH despite semen, and (d) is antimicrobial and contraceptive without adding separate antimicrobial/contraceptive agents (subject to dependent claims that permit added actives). It covers both preformulated “composition” and “solid composition” (dispersible) presentations, plus a method of administration/use.
Independent claim coverage (what’s protected)
US 6,706,276 claim structure (user-provided):
- Claim 1: Antimicrobial + contraceptive composition for reducing transmission and infection risk of STDs via sex involving vagina and penis; vaginally suitable; forms semisolid matrix on semen contact; hardens cervical mucus; forms bio-adhesive layer; maintains acidic vaginal pH (<5) in presence of semen; hypertonic; antimicrobial and contraceptive without addition of antimicrobial or contraceptive agents; matrix-forming polymer + bio-adhesive polymer + buffering agent + water in defined % ranges.
- Claim 11: Corresponding method of reducing risk by administering effective amount prior to or shortly after sex, with identical composition limitations.
- Claim 21: Antimicrobial + contraceptive composition variant with explicit inclusion framework for optional humectant/preservative and an optional “antimicrobial or contraceptive agent” (0-10% by claim language), plus the same matrix/bioadhesion/buffering/pH/hypertonic functional requirements.
- Claim 25: Solid composition that is readily dispersible in aqueous medium to provide in situ dispersed composition with the same matrix/bioadhesion/buffering/pH/hypertonic/semisolid/mucus hardening/bioadhesive/hypertonic requirements; no “antimicrobial or contraceptive agent addition” unless dependents add them.
Implication for scope: Practically, infringement risk tracks whether a product is (i) vaginally applied, (ii) hypertonic, (iii) buffered acidic and maintains pH under semen load, (iv) uses one of the listed matrix-formers and one of the listed bio-adhesives at claimed levels, and (v) exhibits semisolid matrix formation and cervical mucus hardening plus bioadhesion.
Core component Markush breadth
The claims use multiple Markush lists. Under US claim construction norms, infringement exposure remains if an accused formulation uses any one listed species for each functional role.
Matrix-forming agents (claims 1/11/21/25):
- alginic acid
- chitosan
- gellan gum
- poloxamer
Bio-adhesive agents (claims 1/11/21/25):
- xanthan gum
- hydroxypropyl cellulose
- hydroxypropyl methyl cellulose
- sodium carboxymethyl cellulose
- chitosan
- polycarbophil
- crosslinked polyacrylic acid
Buffering agents (claims 1/11/21/25):
- lactic acid
- citric acid
- potassium acid tartrate
- benzoic acid
- alginic acid
- sorbic acid
- fumaric acid
- ascorbic acid
- stearic acid
- oleic acid
- tartaric acid
- edetic acid
- malic acid
- (plus benign inclusion of benzoic acid in some dependent sets)
System behavior is also claimed functionally
- semisolid matrix on semen contact
- hardening of cervical mucus
- bio-adhesive layer over vaginal surfaces
- acidic pH (<5; preferred 3.5-4.5) maintained in semen presence
- hypertonic
- “antimicrobial and contraceptive” property
- “without addition” in claim 1; “with optional addition” in claim 21 and dependents
Numeric ranges and presentation types
- Composition claims 1/11/21: about 1 to about 10% for each of matrix-forming agent, bio-adhesive agent, and buffering agent (water remainder plus optional components).
- Solid claim 25: requires enough matrix/bioadhesion/buffer to yield in-vagina dispersed composition with about 1 to about 10% each of those three key components.
- Dependent “preferred” numerical ranges repeat the same architecture, tightening to:
- matrix-forming agent: about 3 to about 5%
- bio-adhesive: about 2.5 to about 6%
- buffering agent: about 1 to about 7%
- humectant: about 6 to about 10%
- preservative: about 0.1 to about 1%
- optional antimicrobial/contraceptive agent: about 0.2 to about 5%
- and pH in semen presence: about 3.5 to about 4.5
- plus “does not significantly impair natural microbiological balance”
What do the dependent claims add: humectants, preservatives, optional actives, and tighter pH/microbiome constraints?
Short answer. Dependent claims substantially expand the “design space” by explicitly listing humectants and preservatives and by naming specific antimicrobial or contraceptive actives. They also tighten pH behavior and add a microbiome-sparing limitation.
Humectant and preservative dependent coverage
Claim 2/12/22/26: add humectant + preservative.
Key coverage consequence: If an accused product uses any listed humectant and preservative within allowed ranges, it fits additional dependent layers, even if the formulation’s novelty lies in the polymer/buffer system.
Optional antimicrobial/contraceptive agent expansion
Claims 3/13/4/14 and 7/17 and corresponding solid variants add an “antimicrobial or contraceptive agent” option.
Large Markush list (claim 9/19/33): includes surfactant microbicides and multiple antifungal/antiprotozoal/antimicrobial actives:
- nonoxynol-9
- octoxynol-9
- benzalkonium chloride
- phosphorylated hesperidins
- sulfonated hesperidins
- polystyrene sulfonates
- substituted benzenesulfonic acid formaldehyde co-polymers
- H2SO4-modified mandelic acids
- povidone iodine
- itraconazole
- ketoconazole
- metronidazole
- clotrimazole
- fluconazole
- teraconazole
- miconazole
- tinidazole
- iconazole
- chloramphenicol
- nystatin
- cyclopiroxolamine
Tighter enumerations in later dependents (claim 10/20/24/34):
- reduce the optional actives set to a subset focused on nonoxynol-9, octoxynol-9, benzalkonium chloride, phosphorylated/sulfonated hesperidins, polystyrene sulfonates, certain sulfonated benzenesulfonic acid formaldehyde copolymers, and H2SO4-modified mandelic acids, plus sometimes omitting the antifungal/antiprotozoal remainder.
Key design implication: Any vaginal microbicide or contraceptive additive that matches the Markush list creates an “overlay” infringement risk where the base matrix/buffer/pH/hypertonicity and semen-resistant acidic pH constraints are also met.
pH and microbiological balance dependent limitations
Claim 5/15/29/?? (as provided):
- pH range: about 3.5 to 4.5
- “does not significantly impair the natural microbiological balance within the vagina”
Operational effect on claim validity and infringement:
- These are functional/product-property limitations. They can narrow scope to formulations that maintain low pH against semen and do not heavily disrupt the vaginal microbiota.
- For an infringement position, these limitations typically depend on formulation testing or clinical/biological characterization demonstrating pH maintenance and microbiome compatibility.
Where is the “line” between claims 1 and 21: no added actives vs optional actives?
Short answer. Claim 1 requires “antimicrobial and contraceptive without addition of antimicrobial or contraceptive agents.” Claim 21 allows a separate “antimicrobial or contraceptive agent” component at 0 to about 10%.
Practical claim partitioning
- Claim 1 (no added actives):
- The antimicrobial and contraceptive effect is attributed to the base composition properties: polymer matrix + bioadhesive layer + acidic buffering + hypertonicity + semen-contact hardening/matrix formation.
- Claim 21 (optional actives):
- The formulation can include antimicrobial/contraceptive agent as an additional ingredient, while still requiring all of the matrix/bioadhesion/buffer/pH/hypertonic/semisolid/mucus hardening properties.
Business/legal implication: Product developers who use common spermicides or microbicides (e.g., nonoxynol-9 or similar surfactants) face risk that both the “base concept” and the “option with added actives” are covered.
How does the solid dosage form claim work, and what does “readily dispersable” change?
Short answer. Claim 25 recasts the technology into a powder/granule/tablet form that disperses in aqueous medium inside or outside the vagina to yield the same in situ semisolid matrix and pH/hardening/bioadhesion behavior.
Key additional element in claim 25
- The solid composition is “readily dispersable in aqueous based medium either outside or inside the vagina to form a dispersed composition.”
- It must contain sufficient quantities of matrix-forming/bioadhesive/buffering components to yield the in-vagina dispersed composition percentages.
Dosage presentation dependents
- Claims 35-36 add: tablet inserted into the vagina.
Infringement relevance: A competitor can try to avoid “composition” liquid/semi-solid infringement by using a solid pre-dispersion format. Claim 25 and its dependents are designed to capture that fallback.
What is the functional claim theme: semisolid matrix + semen-triggered hardening + acidic hypertonic environment?
Short answer. The patent’s claim logic requires multiple functional outcomes in combination: semen contact triggers matrix formation, cervical mucus hardens, the vaginal environment stays acidic (pH <5 or pH 3.5-4.5), and hypertonicity supports antimicrobial/contraceptive effects.
Functional outcomes and likely test correlates
- Semisolid matrix on semen contact
- in vitro mixing of formulation with semen simulant and observation of gel/viscosity/matrix formation.
- Hardening of cervical mucus
- ex vivo or in vitro rheology/gelation on cervical mucus analogs or collected cervical mucus samples.
- Bio-adhesive layer
- tackiness/adhesion tests on vaginal tissue or mucin analogs.
- Acidic pH maintenance
- pH measurement after semen exposure.
- Hypertonicity
- osmolarity/tonicity evaluation relative to semen/vaginal fluid.
- Antimicrobial and contraceptive
- microbiological assays and contraceptive/spermicidal functional assays.
- No significant microbiological impairment
- community impact studies (often lactobacilli compatibility or broader microbiome markers).
How strong is the US patent estate for this technology, based on claim design?
Short answer. The claim language is broad on composition ingredients (Markush lists) and broad on component roles (matrix forming, bio-adhesion, buffering). It adds several “anchor” functional limitations that are harder to satisfy by random vaginal formulations, which increases validity defensibility if those anchors were supported by data.
Strength drivers (from claim content)
- Multiple independent claims: composition (liquid/semi-solid), method, composition with optional actives, solid dispersible.
- Multiple dependent claims create a lattice: humectant/preservative and optional actives expand “within-technology” coverage.
- Functional constraints (pH maintenance in semen presence, cervical mucus hardening, matrix formation, hypertonicity, antimicrobial+contraceptive effect) reduce the chance of trivial design-arounds that keep only the polymer/buffer pieces.
Primary vulnerability vectors (from claim content)
- Broad “about” ranges and large Markush sets can be challenged for enablement/indefiniteness or overbreadth, but enforcement typically focuses on compositions that also achieve the stated functional outcomes.
- Product-property claim elements like “does not significantly impair natural microbiological balance” can increase evidentiary requirements for an infringement claim.
(These are litigation and prosecution considerations inferred from claim structure.)
What generic or competitive entry risks exist if a product matches the polymer/buffer/hypertonic pH behavior?
Short answer. Risk is high for any vaginal prophylactic/contraceptive product using the claimed matrix-former + bioadhesive polymer + acidic buffer system in hypertonic conditions that maintain acidic pH in semen exposure and cause cervical mucus hardening.
Most direct infringement fact pattern
- Uses alginic acid (or chitosan/gellan gum/poloxamer) as matrix-former
- Uses xanthan gum or hydroxypropyl cellulose (or other listed bioadhesives)
- Uses lactic acid/citric acid/potassium acid tartrate (or other listed buffers)
- Includes humectant and preservative within listed categories and ranges
- Uses optional microbicide/spermicide actives from the listed Markush sets (or omits actives and relies on acid/hypertonicity alone)
- Maintains vaginal pH 3.5-4.5 (in semen presence) without significant microbiome impairment (if pursuing dependent-claim coverage)
Common design-arounds and their likely limitations under this claim language
- Changing polymers outside Markush sets: reduces likelihood unless functional outcomes are still matched by listed species (not covered by this patent).
- Reformulating pH: if pH cannot be maintained <5 (or 3.5-4.5), functional limitations fail.
- Avoiding semen-triggered semisolid matrix: if no matrix formation or mucus hardening, key anchors fail.
- Solid-to-liquid changes: solid forms are covered by claim 25, tablets by dependent 35-36.
How do you operationalize the claim elements for infringement mapping and freedom-to-operate?
Short answer. Treat the patent like a matrix: match each element in priority order, then verify dependent-range and optional-component coverage.
Element-by-element claim checklist (US 6,706,276)
- Vaginal application for sex involving vagina and penis (STD risk reduction + contraceptive)
- Hypertonic
- Semisolid matrix on semen contact (or dispersed-to-semisonic behavior for solid claim)
- Hardening of cervical mucus
- Bio-adhesive layer over vaginal surfaces
- Acidic vaginal pH maintained in semen presence
- Claim 1/11/21/25: pH <5
- Claim 5/15/22/29/30/31/??: pH 3.5-4.5 and microbiome preservation
- Polymer/buffer system
- Matrix-former species in claimed % range
- Bio-adhesive species in claimed % range
- Buffer species in claimed % range
- Water and optional additional components
- humectant category and range (dependent claims)
- preservative category and range (dependent claims)
- optional antimicrobial/contraceptive agent category and range (dependent claims)
When does exclusivity end, and what is the Orange Book / Hatch-Wax relevance for this patent?
Short answer (based on provided information). Nothing in the prompt identifies an FDA-approved drug product, NDC, reference listed drug, Orange Book listing, or Hatch-Wax exclusivity period tied to US 6,706,276. Without that product linkage, the exclusivity and Orange Book status cannot be determined from the claim text alone.
Which companies are challenging this patent via Paragraph IV, and what litigation affects its scope?
Short answer (based on provided information). The prompt does not include any patent litigation records, PTAB filings, district court case captions, Paragraph IV notices, settlements, or assignee/company mapping. Without that, a company-by-company challenge landscape cannot be produced.
Key Takeaways
- US 6,706,276 protects a vaginal antimicrobial-contraceptive system built around a hypertonic, acidic, buffered, bio-adhesive and matrix-forming polymer combination that forms a semisolid matrix on semen contact, hardens cervical mucus, and maintains acidic vaginal pH under semen exposure.
- The patent’s breadth comes from Markush ingredient lists for matrix-formers, bio-adhesives, buffers, humectants, preservatives, and optional actives, combined with functional anchors (semen-triggered matrix formation, mucus hardening, pH maintenance, bioadhesion, hypertonicity, antimicrobial/contraceptive performance).
- Independent coverage exists for (i) compositions, (ii) a corresponding method, (iii) a variant allowing optional antimicrobial/contraceptive agents, and (iv) solid dispersible formulations including tablets.
- Main infringement risk concentrates on products that can demonstrate the claimed functional performance in semen presence, especially acidic pH maintenance (<5 or 3.5-4.5) and cervical mucus hardening.
FAQs
-
Can a formulation that uses only chitosan and lactic acid still fall within claim 1?
Coverage depends on using a listed matrix-former, a listed bio-adhesive agent from the claim’s set, and meeting the functional requirements (semisolid matrix on semen contact, mucus hardening, hypertonicity, and acidic pH maintenance).
-
Does claim 25 cover tablets that dissolve in the vagina?
Yes. It covers solids that are “readily dispersable” to form the dispersed composition that reproduces the claimed in-vagina matrix/bioadhesion/buffer/pH/hypertonic and functional outcomes; dependent claims specify “tablet” inserted into the vagina.
-
If a product includes nonoxynol-9, which claim pathways are triggered?
It can trigger dependent claim sets that list nonoxynol-9 as an “antimicrobial or contraceptive agent,” provided the base matrix/bioadhesion/buffering/pH/hypertonic/semisolid/mucus hardening constraints are met.
-
What is the difference between “pH less than about 5” and “about 3.5 to about 4.5” within the claim system?
The broader “<5” language is used in core independents. The narrower 3.5-4.5 window appears in dependent claims, coupled with the added microbiological balance limitation.
-
How does the “without addition of antimicrobial or contraceptive agents” limitation constrain design-arounds?
Claim 1 requires the antimicrobial/contraceptive effect without adding a separate antimicrobial/contraceptive agent. Products that include one of the listed optional actives are better evaluated against the claim set that expressly permits such additions.
References (APA)
- U.S. Patent No. 6,706,276.
